

### Epidemiology

Microsporidia are protists related to fungi, defined by the presence of a unique invasive organelle consisting of a single polar tube that coils around the interior of the spore. They are ubiquitous organisms and are likely zoonotic and/or waterborne in origin. Phylogenetic studies now place microsporidia with the Cryptomycota as the basal branch of the fungal kingdom (or alternatively as a sister phylum).<sup>1</sup> The microsporidia reported as pathogens in humans include *Encephalitozoon cuniculi*, *Encephalitozoon hellem*, *Encephalitozoon* (syn *Septata*) *intestinalis*, *Enterocytozoon bienewisi*, *Trachipleistophora hominis*, *Trachipleistophora anthropophthera*, *Pleistophora* species, *P. ronneafiei*, *Vittaforma* (syn *Nosema*) *corneae*, *Tubulonosema acridophagus*, *Endoreticulatus* sp., *Nosema ocularum*, *Anncaliia* (syns *Brachiola/Nosema*) *connori*, *Anncaliia* (syn *Brachiola*) *vesicularum*, *Anncaliia* (syns *Brachiola/Nosema*) *algerae*, and *Microsporidium* sp.<sup>2-8</sup> In the pre-antiretroviral therapy (ART) era, reported prevalence rates of microsporidiosis varied between 2% and 70% among patients with HIV with diarrhea, depending on the diagnostic techniques employed and the patient population described.<sup>3-5,8</sup> The incidence of microsporidiosis has declined with the widespread use of effective ART, but continues to occur among patients with HIV who are unable to obtain ART or to remain on it.<sup>9</sup> Microsporidiosis is increasingly recognized among persons without HIV, including children, travelers, organ transplant recipients, contact lens wearers, and the elderly. In patients with immune suppression, clinical signs related to microsporidiosis are most commonly observed when CD4 T lymphocyte cell (CD4) counts are <100 cells/mm<sup>3</sup>.<sup>3-5,8</sup>

### Clinical Manifestations

The most common manifestation of microsporidiosis is gastrointestinal tract infection with diarrhea; however, encephalitis, ocular infection, sinusitis, myositis, and disseminated infection have also been described.<sup>3-5,8</sup>

Clinical syndromes can vary by infecting species. *E. bienewisi* is associated with malabsorption, diarrhea, and cholangitis. *E. cuniculi* is associated with hepatitis, encephalitis, and disseminated disease. *E. intestinalis* is associated with diarrhea, disseminated infection, and superficial keratoconjunctivitis. *E. hellem* is associated with superficial keratoconjunctivitis, sinusitis, respiratory disease, prostatic abscesses, and disseminated infection. *Anncaliia*, *Vittaforma*, and *Trachipleistophora* are associated with keratoconjunctivitis. *Nosema*, *Vittaforma*, and *Microsporidium* are associated with stromal keratitis following trauma in immunocompetent hosts. *Pleistophora*, *Anncaliia*, and *Trachipleistophora* are associated with myositis. *Trachipleistophora* is associated with encephalitis and disseminated disease.

### Diagnosis

Effective morphologic demonstration of microsporidia by light microscopy can be accomplished with staining methods that produce differential contrast between the spores of the microsporidia and the cells and debris in clinical samples such as stool. In addition, because of the small size of the spores (1–5 μm), magnification up to 1,000 times is required for visualization. Chromotrope 2R and the fluorescent brighteners calcofluor white and Uvitex 2B are useful as selective stains for microsporidia in stool and other body fluids.<sup>7</sup>

In biopsy specimens, microsporidia can be visualized with Giemsa, tissue Gram stains (Brown-Hopps Gram stain), calcofluor white or Uvitex 2B (fluorescent brighteners) staining, Warthin-Starry silver staining, or Chromotrope 2A.<sup>7</sup> In gastrointestinal disease, examination of three stools with chromotrope and chemofluorescent stains is often sufficient for diagnosis. If stool examination is negative and microsporidiosis is suspected, a small bowel biopsy may be useful. If the etiologic agent is *Encephalitozoon* or *Trachipleistophora* sp., examination of urine often also reveals the organism. Determination of the

species of microsporidia causing disease can be made by the morphology of the organism demonstrated by transmission electron microscopy, by staining with species-specific antibodies, or by polymerase chain reaction using species- or genus-specific primers.<sup>7,10</sup> Assistance of specialists familiar with the species differentiation of microsporidia should be sought.

## Preventing Exposure

Patients with AIDS who have CD4 counts <200 cells/mm<sup>3</sup> should avoid untreated water sources (**AIII**). Additional recommendations include general attention to hand washing and personal hygiene, avoiding eating undercooked meat or seafood, and limiting exposure to animals known to be infected with microsporidia (**BIII**).<sup>11</sup> The precautions described in the section on cryptosporidiosis also are applicable to microsporidiosis.

## Preventing Disease

Because chronic microsporidiosis occurs primarily in patients with advanced immunodeficiency, appropriate initiation of ART before the patient becomes severely immunosuppressed should prevent this disease (**AII**). No specific chemoprophylactic regimens are known to be effective in preventing microsporidiosis.

## Treating Disease

Data suggest that treatment with ART enables a patient's own defenses to eradicate microsporidia,<sup>12,13</sup> and administration of ART with immune restoration (an increase in CD4 count to >100 cells/mm<sup>3</sup>) is associated with resolution of symptoms of enteric microsporidiosis, including illness caused by *E. bienersi*.<sup>12-15</sup> All patients therefore should be offered ART as part of the initial management of microsporidial infection (**AII**). They should be given fluid support if they have signs of diarrhea and dehydration (**AII**). Patients with malnutrition and wasting should be treated with nutritional supplementation (**AIII**). Antimotility agents can be used if required for diarrhea control (**BIII**).

No specific therapeutic agent is available for *E. bienersi* infection. A controlled clinical trial suggested that *E. bienersi* infection may respond to oral fumagillin (60 mg/day), a water-insoluble antibiotic made by *Aspergillus fumigatus* (**BII**),<sup>16,17</sup> or to its synthetic analog, TNP-470 (**BIII**).<sup>18</sup> Fumagillin and TNP-470 are not commercially available for systemic use in the United States. However, fumagillin is available from Sanofi in France as FLISINT<sup>®</sup> 20 mg, capsules and has been obtained for patients in the United States (see Sanofi's [Compassionate Use/Managed Access Program](#) website). One report indicated that treatment with nitazoxanide might resolve chronic diarrhea caused by *E. bienersi* in the absence of ART;<sup>19</sup> however, the effect appeared to be minimal among patients with low CD4 cell counts. Based on personal experience of several experts who have treated diarrhea caused by *E. bienersi* with nitazoxanide in organ transplant patients, nitazoxanide is a reasonable alternative, if fumagillin is not available, for the treatment of diarrhea due to *E. bienersi* (**CIII**).

Albendazole, a benzimidazole that binds to  $\beta$ -tubulin, has activity against many species of microsporidia, but it is not effective against *Enterocytozoon* or *V. corneae* infections. The tubulin genes of both *E. bienersi*<sup>20</sup> and *V. corneae*<sup>21</sup> have amino acid residues associated with albendazole resistance. Albendazole is only recommended for initial therapy of intestinal and disseminated microsporidiosis caused by microsporidia other than *E. bienersi* and *V. corneae* (**AII**).<sup>22-24</sup>

Itraconazole may be useful in disseminated disease when combined with albendazole, especially in infections caused by *Trachipleistophora* or *Anncaliia* (**CIII**). Treatment with furazolidone (an agent that is not currently available in the United States) combined with albendazole was reported to improve clinical signs in four patients with HIV with persistent diarrhea and *E. bienersi* infection (**CIII**);<sup>25</sup> however, furazolidone has not been demonstrated to be active in other case reports. Metronidazole and atovaquone are not active *in vitro* or in animal models and **should not be used** to treat microsporidiosis (**AII**).

Ocular infections caused by microsporidia should be treated with topical Fumidil B (fumagillin bicyclohexylammonium) in saline (to achieve a concentration of 70 µg/mL of fumagillin) **(BII)**.<sup>22</sup> Topical fumagillin solution needs to be made by a compounding pharmacy as it is not commercially available in the United States and is investigational. Although clearance of microsporidia from the eye can be demonstrated, the organism often is still present systemically and can be detected in urine or in nasal smears. Therefore, the use of albendazole as a companion systemic agent to fumagillin is recommended in ocular infections **(BIII)**.

### ***Special Considerations with Regard to Starting ART***

As noted above, all patients should be offered ART as part of the initial management of microsporidial infection and fluid support if they have signs of diarrhea and dehydration **(AII)**. Data suggest that treatment with ART, which results in immune reconstitution, enables a patient's own defenses to eradicate microsporidia.<sup>12,13</sup>

### ***Monitoring of Response to Therapy and Adverse Events (Including IRIS)***

Although side effects with albendazole are rare, hepatic enzymes should be monitored because elevations have been reported. Albendazole is not known to be carcinogenic or mutagenic. Topical fumagillin has not been associated with substantial side effects. Oral fumagillin has been associated with thrombocytopenia, which is reversible on stopping the drug.

One report of immune reconstitution inflammatory syndrome (IRIS) has been described in a patient with HIV treated with ART in the setting of *E. bienersi* infection;<sup>26</sup> however, no IRIS reactions have been reported with other species of microsporidia or with other cases of *E. bienersi*. Concerns about IRIS should not alter therapy or the institution of ART **(AIII)**.

### ***Managing Treatment Failure***

Supportive treatment and optimization of ART to attempt to achieve full virologic suppression are the only currently feasible approaches to managing treatment failure **(AIII)**.

## **Preventing Recurrence**

In individuals with relatively competent immune systems (>200 CD4 cells/mm<sup>3</sup>), treatment can probably be discontinued after ocular infection resolves **(CIII)**, but it should be continued indefinitely if CD4 counts fall below 200 cells/mm<sup>3</sup> blood because recurrence or relapse may occur after treatment discontinuation **(BIII)**. Whether it is safe to discontinue treatment for other manifestations after immune restoration with ART is unknown. Based on experience with discontinuation of secondary prophylaxis for other opportunistic infections, it is reasonable to discontinue chronic maintenance therapy in patients who no longer have signs and symptoms of microsporidiosis and have a sustained increase in their CD4 counts to >200 cells/mm<sup>3</sup> for 6 months after ART **(BIII)**.<sup>13</sup>

## **Special Considerations During Pregnancy**

Rehydration and initiation of ART should be the mainstays of initial treatment of microsporidiosis during pregnancy, as in nonpregnant women **(AII)**. In rats and rabbits, albendazole is embryotoxic and teratogenic at exposure levels less than those estimated with therapeutic human dosing. There are no adequate and well-controlled studies of albendazole exposure in early human pregnancy. A recent randomized trial in which albendazole was used for second-trimester treatment of soil-transmitted helminth infections found no evidence of teratogenicity or other adverse pregnancy effects.<sup>27</sup>

Based on these data, albendazole **is not recommended** for use during the first trimester **(BIII)**; use in later pregnancy should be considered only if benefits are felt to outweigh potential risk **(CIII)**. Systemic fumagillin has been associated with increased resorption and growth retardation in rats. No data on use in human pregnancy are available. However, because of the antiangiogenic effect of fumagillin, this drug

**should not be used** systemically in pregnant women (**AIII**). Topical fumagillin has not been associated with embryotoxic or teratogenic effects and can be considered when therapy with this agent is appropriate (**CIII**). Furazolidone is not teratogenic in animal studies, but human data are limited to a case series that found no association between first-trimester use of furazolidone and birth defects in 132 furazolidone-exposed pregnancies.<sup>28</sup> Nitazoxanide has not been associated with adverse outcomes in pregnancy and is a category B drug; however, data are very limited on its use during pregnancy (**CIII**). Case reports exist of birth defects in infants exposed to itraconazole, but prospective cohort studies of >300 women with first-trimester exposure did not show an increased risk of malformation.<sup>29,30</sup> In general, however, azole antifungals should be avoided during the first trimester (**BIII**). Loperamide is poorly absorbed and has not been associated with birth defects in animal studies. However, a recent study identified an increased risk of congenital malformations, and specifically hypospadias, among 683 women with exposure to loperamide early in pregnancy.<sup>31</sup> Therefore, loperamide should be avoided in the first trimester, unless benefits are felt to outweigh potential risks (**CIII**). Loperamide is the preferred antimotility agent in late pregnancy (**CIII**). Opiate exposure in late pregnancy has been associated with neonatal respiratory depression, and chronic exposure may result in neonatal withdrawal, therefore tincture of opium **is not recommended** in late pregnancy (**AIII**).

### Recommendations for Managing Microsporidiosis

<p><b>Preventing Chronic Microsporidiosis:</b></p> <ul style="list-style-type: none"> <li>• Because chronic microsporidiosis occurs primarily in persons with advanced immunodeficiency, initiation of ART before the patient becomes severely immunosuppressed should prevent the disease (<b>AII</b>).</li> </ul>
<p><b>Managing Microsporidiosis:</b></p> <ul style="list-style-type: none"> <li>• Initiate or optimize ART with immune restoration to CD4 count &gt;100 cells/mm<sup>3</sup> (<b>AII</b>).</li> <li>• Severe dehydration, malnutrition, and wasting should be managed by fluid support (<b>AII</b>) and nutritional supplements (<b>AIII</b>).</li> <li>• Anti-motility agents can be used for diarrhea control, if required (<b>BIII</b>).</li> </ul> <p><i>For GI Infections Caused by Enterocytozoon bienersi</i></p> <ul style="list-style-type: none"> <li>• The best treatment option is ART and fluid support (<b>AII</b>).</li> <li>• No specific therapeutic agent is available for this infection.</li> <li>• Fumagillin 60 mg PO daily (<b>BII</b>) and TNP-470 (<b>BIII</b>) are two agents that are effective, but neither agent is available in the United States.</li> <li>• Nitazoxanide can have a therapeutic effect, but this efficacy has been limited in patients with low CD4 cell counts (<b>CIII</b>).</li> </ul> <p><i>For Intestinal and Disseminated (Not Ocular) Infection Caused by Microsporidia Other Than E. bienersi and Vitaforma corneae:</i></p> <ul style="list-style-type: none"> <li>• Albendazole 400 mg PO twice daily (<b>AII</b>), continue until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;6 months after initiation of ART (<b>BIII</b>)</li> </ul> <p><i>For Disseminated Disease Caused by Trachipleistophora or Anncaliia:</i></p> <ul style="list-style-type: none"> <li>• Itraconazole 400 mg PO daily plus albendazole 400 mg PO two times a day (<b>CIII</b>)</li> </ul> <p><i>For Ocular Infection:</i></p> <ul style="list-style-type: none"> <li>• Topical fumagillin bicylohexylammonium (Fumidil B) 3 mg/mL in saline (fumagillin 70 µg/mL) eye drops: 2 drops every 2 hours for 4 days, then 2 drops four times daily (investigational use only in United States) (<b>BII</b>), plus albendazole 400 mg PO twice daily for management of systemic infection (<b>BIII</b>)</li> <li>• For patients with CD4 count &gt;200 cells/mm<sup>3</sup>, therapy can probably be discontinued after ocular infection resolves (<b>CIII</b>).</li> <li>• For patients with CD4 count ≤200 cells/mm<sup>3</sup>, therapy should be continued until resolution of ocular symptoms and CD4 count increases to &gt;200 cells/mm<sup>3</sup> for ≥6 months in response to ART (<b>BIII</b>).</li> </ul>

**Key:** ART = antiretroviral therapy; CD4 = CD4 T lymphocyte; GI = gastrointestinal; PO = orally

## References

1. James TY, Pelin A, Bonen L, et al. Shared signatures of parasitism and phylogenomics unite Cryptomycota and microsporidia. *Curr Biol*. 2013;23(16):1548-1553. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23932404>.
2. Beauvais B, Sarfati C, Molina JM, Lesourd A, Lariviere M, Derouin F. Comparative evaluation of five diagnostic methods for demonstrating microsporidia in stool and intestinal biopsy specimens. *Ann Trop Med Parasitol*. 1993;87(1):99-102. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8346996>.
3. Deplazes P, Mathis A, Weber R. Epidemiology and zoonotic aspects of microsporidia of mammals and birds. *Contrib Microbiol*. 2000;6:236-260. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10943515>.
4. Kotler DP, Orenstein JM. Clinical syndromes associated with microsporidiosis. *Adv Parasitol*. 1998;40:321-349. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9554078>.
5. Mathis A. Microsporidia: emerging advances in understanding the basic biology of these unique organisms. *Int J Parasitol*. 2000;30(7):795-804. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10899524>.
6. Weber R, Bryan RT, Owen RL, Wilcox CM, Gorelkin L, Visvesvara GS. Improved light-microscopical detection of microsporidia spores in stool and duodenal aspirates. The Enteric Opportunistic Infections Working Group. *N Engl J Med*. 1992;326(3):161-166. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/1370122>.
7. Weiss LM, Vossbrinck CR. Microsporidiosis: molecular and diagnostic aspects. *Adv Parasitol*. 1998;40:351-395. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9554079>.
8. Wittner M, Weiss L. *The Microsporidia and Microsporidiosis*. Washington DC: ASM Press; 1999.
9. Stark D, Barratt JL, van Hal S, Marriott D, Harkness J, Ellis JT. Clinical significance of enteric protozoa in the immunosuppressed human population. *Clin Microbiol Rev*. 2009;22(4):634-650. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19822892>.
10. Sheoran AS, Feng X, Singh I, et al. Monoclonal antibodies against *Enterocytozoon bienewsi* of human origin. *Clin Diagn Lab Immunol*. 2005;12(9):1109-1113. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16148179>.
11. Didier ES, Weiss LM. Microsporidiosis: current status. *Curr Opin Infect Dis*. 2006;19(5):485-492. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16940873>.
12. Goguel J, Katlama C, Sarfati C, Maslo C, Leport C, Molina JM. Remission of AIDS-associated intestinal microsporidiosis with highly active antiretroviral therapy. *AIDS*. 1997;11(13):1658-1659. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9365777>.
13. Miao YM, Awad-El-Kariem FM, Franzen C, et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2000;25(2):124-129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11103042>.
14. Contreas CN, Berlin OG, Speck CE, Pandhumas SS, Lariviere MJ, Fu C. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. *Am J Trop Med Hyg*. 1998;58(5):555-558. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9598440>.
15. Maggi P, Larocca AM, Quarto M, et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. *Eur J Clin Microbiol Infect Dis*. 2000;19(3):213-217. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10795595>.
16. Molina JM, Goguel J, Sarfati C, et al. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. ANRS 054 Study Group. Agence Nationale de Recherche sur le SIDA. *AIDS*. 2000;14(10):1341-1348. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10930148>.
17. Molina JM, Tourneur M, Sarfati C, et al. Fumagillin treatment of intestinal microsporidiosis. *N Engl J Med*. 2002;346(25):1963-1969. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12075057>.
18. Didier PJ, Phillips JN, Kuebler DJ, et al. Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives *in vitro* and *in vivo*. *Antimicrob Agents Chemother*. 2006;50(6):2146-2155. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16723577>.
19. Bicart-See A, Massip P, Linas MD, Darty A. Successful treatment with nitazoxanide of *Enterocytozoon bienewsi* microsporidiosis in a patient with AIDS. *Antimicrob Agents Chemother*. 2000;44(1):167-168. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10602740>.

20. Akiyoshi DE, Weiss LM, Feng X, et al. Analysis of the beta-tubulin genes from *Enterocytozoon bienewisi* isolates from a human and rhesus macaque. *J Eukaryot Microbiol.* 2007;54(1):38-41. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17300517>.
21. Franzen C, Salzberger B. Analysis of the beta-tubulin gene from *Vittaforma corneae* suggests benzimidazole resistance. *Antimicrob Agents Chemother.* 2008;52(2):790-793. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18056284>.
22. Diesenhouse MC, Wilson LA, Corrent GF, Visvesvara GS, Grossniklaus HE, Bryan RT. Treatment of microsporidial keratoconjunctivitis with topical fumagillin. *Am J Ophthalmol.* 1993;115(3):293-298. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8117342>.
23. Dieterich DT, Lew EA, Kotler DP, Poles MA, Orenstein JM. Treatment with albendazole for intestinal disease due to *Enterocytozoon bienewisi* in patients with AIDS. *J Infect Dis.* 1994;169(1):178-183. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8277179>.
24. Molina JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to *Encephalitozoon intestinalis* in patients with AIDS: a randomized double-blind controlled trial. *J Infect Dis.* 1998;177(5):1373-1377. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9593027>.
25. Dionisio D, Manneschi LI, Di Lollo S, et al. Persistent damage to *Enterocytozoon bienewisi*, with persistent symptomatic relief, after combined furazolidone and albendazole in AIDS patients. *J Clin Pathol.* 1998;51(10):731-736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10023334>.
26. Sriaroon C, Mayer CA, Chen L, Accurso C, Greene JN, Vincent AL. Diffuse intra-abdominal granulomatous seeding as a manifestation of immune reconstitution inflammatory syndrome associated with microsporidiosis in a patient with HIV. *AIDS Patient Care STDS.* 2008;22(8):611-612. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18627278>.
27. Ndyomugenyi R, Kabatereine N, Olsen A, Magnussen P. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. *Am J Trop Med Hyg.* 2008;79(6):856-863. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19052293>.
28. Heinonen OP, Slone D, Shapiro S. *Birth Defects and Drugs in Pregnancy.* Littleton: Publishing Sciences Group; 1977.
29. De Santis M, Di Gianantonio E, Cesari E, Ambrosini G, Straface G, Clementi M. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. *Drug Saf.* 2009;32(3):239-244. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19338381>.
30. Bar-Oz B, Moretti ME, Bishai R, et al. Pregnancy outcome after *in utero* exposure to itraconazole: a prospective cohort study. *Am J Obstet Gynecol.* 2000;183(3):617-620. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10992182>.
31. Kallen B, Nilsson E, Otterblad Olausson P. Maternal use of loperamide in early pregnancy and delivery outcome. *Acta Paediatr.* 2008;97(5):541-545. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18394096>.